<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01966159</url>
  </required_header>
  <id_info>
    <org_study_id>S2279</org_study_id>
    <nct_id>NCT01966159</nct_id>
  </id_info>
  <brief_title>The EVOLVE China Clinical Trial</brief_title>
  <acronym>EVOLVE-CHINA</acronym>
  <official_title>EVOLVE China: A Prospective, Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of the SYNERGY™ Coronary
      Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length
      (by visual estimate) in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual
      estimate)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EVOLVE China clinical trial is designed to assess the safety and effectiveness of the
      SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System for the treatment of
      subjects with atherosclerotic lesion(s) in native coronary arteries in China. The SYNERGY™
      Stent System (Boston Scientific Corporation [BSC Corporation], Natick, Massachusetts, United
      States) is based on the well characterized Element™ stent platform and utilizes a
      bioabsorbable poly(DL-lactide-co-glycolide) (PLGA) polymer to deliver everolimus.

      While SYNERGY is a new generation DES, the safety and effectiveness of the Element stent
      platform in combination with everolimus in the form of the PROMUS Element stent has been
      established in the PLATINUM Clinical Trial Program.The PROMUS Element Plus stent (control
      device) uses the same stent platform as PROMUS Element stent with a modified balloon
      component on the Stent Delivery System to improve overall system deliverability. In addition,
      the previous version of the SYNERGY stent, the SYNERGY First Human Use stent (SYNERGY FHU
      stent) has been investigated in the EVOLVE FHU trial which has completed its primary endpoint
      and demonstrated comparable safety and efficacy profile of SYNERGY FHU to PROMUS Element up
      to 1-year follow-up (28). SYNERGY has been approved by CE Mark.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The In-stent Late Loss Measured by Quantitative Coronary Angiography</measure>
    <time_frame>at 9 months post-index procedure.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR) Rate</measure>
    <time_frame>12 months post-index procedure</time_frame>
    <description>Target lesion revascularization is any ischemia-driven repeat percutaneous intervention, to improve blood flow, of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Target Lesion Failure (TLF) Rate</measure>
    <time_frame>12 months post-index procedure</time_frame>
    <description>Target lesion failure is any ischemia-driven revascularization of the target lesion, MI (Q-wave and non-Q-wave) related to the target vessel, or (cardiac) death.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">412</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>SYNERGY Investigational Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SYNERGY Stent System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PE Plus Investigational Device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PE Plus Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SYNERGY Investigational Device</intervention_name>
    <description>percutaneous coronary intervention</description>
    <arm_group_label>SYNERGY Investigational Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PE Plus Investigational Device</intervention_name>
    <description>percutaneous coronary intervention</description>
    <arm_group_label>PE Plus Investigational Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CI1. Subject must be 18 -75 years of age

          -  CI2. Subject (or legal guardian) understands the trial requirements and the treatment
             procedures and provides written informed consent before any trial-specific tests or
             procedures are performed

          -  CI3. Subject is eligible for percutaneous coronary intervention (PCI)

          -  CI4. Subject has symptomatic coronary artery disease with objective evidence of
             ischemia or silent ischemia

          -  CI5. Subject is an acceptable candidate for coronary artery bypass grafting (CABG)

          -  CI6. Subject is willing to comply with all protocol-required follow-up evaluation

          -  CI7. Subject has a left ventricular ejection fraction (LVEF) &gt;30% as measured within
             60 days prior to enrollment

          -  AI1. Target lesion(s) must be de novo lesion located in a native coronary artery with
             a visually estimated reference vessel diameter (RVD) ≥2.25 mm and ≤4.0 mm

          -  AI2. Target lesion(s) length must be ≤34 mm (by visual estimate)

          -  AI3. Target lesion(s) must have visually estimated stenosis ≥50% and &lt;100% with
             thrombolysis in Myocardial Infarction (TIMI) flow &gt;1 and one of the following:
             stenosis ≥70%, abnormal fractional flow reserve (FFR), abnormal stress or imaging
             stress test, or elevated biomarkers prior to the procedure

          -  AI4. Coronary anatomy is likely to allow delivery of a study device to the target
             lesions(s)

          -  AI5. The first lesion treated must be successfully predilated/pretreated

        Exclusion Criteria:

          -  CE1. Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent
             with acute MI .

          -  CE2. Subject with unstable angina or recent MI (within 1 week) must have CK/CK-MB or
             troponin documented prior to the procedure and are excluded if any of the following
             criteria are met at the time of the index procedure:

               -  If CK MB &gt;2× upper limit of normal (ULN), the subject is excluded regardless of
                  the CK Total.

               -  If CK Total &gt;2× ULN, either CK-MB or troponin must be drawn and the subject is
                  excluded if either CK-MB or troponin is abnormal.

               -  If neither CK Total or CK MB is drawn but troponin is, the subject is excluded if
                  troponin &gt;1× ULN and the subject has at least one of the following:

                    -  Subject has ischemic symptoms and ECG changes indicative of ongoing ischemia
                       (e.g., &gt;1 mm ST segment elevation or depression in consecutive leads or new
                       left bundle branch block [LBBB])

                    -  Development of pathological Q waves in the ECG or

                    -  Imaging evidence of new loss of viable myocardium or new regional wall
                       motion abnormality

          -  CE3. Subject has cardiogenic shock, hemodynamic instability requiring inotropic or
             mechanical circulatory support, or intractable ventricular arrhythmias or ongoing
             intractable angina

          -  CE4. Subject has received an organ transplant or is on a waiting list for an organ
             transplant

          -  CE5. Subject is receiving or scheduled to receive chemotherapy within 30 days before
             or after the index procedure

          -  CE6. Planned PCI or CABG after the index procedure

          -  CE7. Subject has a known allergy to the trial stent system or protocol-required
             concomitant medications (e.g., platinum, platinum-chromium alloy, stainless steel,
             everolimus or structurally related compounds, polymer or individual components,
             clopidogrel, or aspirin) and contrast (that cannot be adequately premedicated)

          -  CE8. Subject has a known condition(s) of the following (as assessed from the time of
             screening through the day of index procedure):

               -  Other serious medical illness (e.g., cancer, congestive heart failure) that may
                  reduce life expectancy to less than 24 months

               -  Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.)

               -  Planned procedure that may cause non-compliance with the protocol or confound
                  data interpretation

          -  CE9. Subject is receiving chronic (≥72 hours) anticoagulation therapy (i.e., heparin,
             Coumadin) for indications other than acute coronary syndrome

          -  CE10. Subject with out of range complete blood count (CBC) values that are determined
             by the study physician to be clinically significant.

          -  CE11. Subject has documented or suspected liver disease, including laboratory evidence
             of hepatitis

          -  CE12. Subject is on dialysis or has baseline serum creatinine level &gt;2.0 mg/dL
             (177µmol/L)

          -  CE13. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood
             transfusions

          -  CE14. Subject has had a history of cerebrovascular accident (CVA) or transient
             ischemic attack (TIA) within the past 6 months

          -  CE15. Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding

          -  CE16. Subject has signs or symptoms of active heart failure (i.e., NYHA class IV) at
             the time of the index procedure

          -  CE17. Subject is participating in another investigational drug or device clinical
             trial that has not reached its primary endpoint

          -  CE18. Subject intends to participate in another investigational drug or device
             clinical trial within 12 months after the index procedure

          -  CE19. Subject with known intention to procreate within 12 months after the index
             procedure (women of child-bearing potential who are sexually active must agree to use
             a reliable method of contraception from the time of screening through 12 months after
             the index procedure)

          -  CE20. Subject is a woman who is pregnant or nursing (a pregnancy test must be
             performed within 7 days prior to the index procedure in women of child-bearing
             potential)

          -  CE21. Target vessel has been treated with any type of PCI (e.g., balloon angioplasty,
             stent, cutting balloon, atherectomy) within 12 months prior to the index procedure

          -  AE1. Planned treatment of more than 2 lesions

          -  AE2. Planned treatment of lesions in more than 2 major epicardial vessels

          -  AE3. Planned treatment of a single lesion with more than 1 stent Note: Planned use of
             2 overlapping stents will be allowed in subjects randomized to PROMUS Element Plus
             where lesion length is ≥28 mm and 2.25 mm stents are used.

          -  AE4. Target lesion meets any of the following criteria:

               -  Left main location

               -  Located within 3 mm of the origin of the left anterior descending (LAD) coronary
                  artery or left circumflex (LCX) coronary artery by visual estimate

               -  Located within a saphenous vein graft or an arterial graft

               -  Will be accessed via a saphenous vein graft or an arterial graft

               -  TIMI flow 0 (total occlusion) or TIMI flow 1 prior to guide wire crossing

               -  Thrombus, or possible thrombus, present in the target vessel

               -  Excessive tortuosity proximal to or within the lesion

               -  Excessive angulation proximal to or within the lesion

               -  Target lesion and/or the target vessel proximal to the target lesion is
                  moderately to severely calcified by visual estimate

               -  Involves a side branch ≥2.0 mm in diameter by visual estimate or a side branch
                  &lt;2.0 mm in diameter by visual estimate which requires treatment

          -  AE5. Target lesion(s) treated during the index procedure that involves a complex
             bifurcation (e.g., bifurcation lesion requiring treatment with more than 1 stent)

          -  AE6. Target lesion(s) is restenostic from a previous stent implantation or study stent
             would overlap with a previous stent

          -  AE7. Subject has unprotected left main coronary artery disease (&gt;50% diameter
             stenosis)

          -  AE8. Subject has protected left main coronary artery disease (&gt;50% diameter stenosis
             in the LMCA with bypass graft(s) to the left coronary artery) and a target lesion in
             the LAD or LCX
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingdong Zhang, MD, MPH, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Affiliated Hospital of Armed Police Medical College</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital of the Ministry of Health</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute and Fu Wai Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daqing General Oil Field Hospital</name>
      <address>
        <city>Daqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Cardiovascular Institute of Guangdong Provincial Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shengyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenyang Northern Hospital (The General Hospital of Shenyang Military Region)</name>
      <address>
        <city>Shen</city>
        <zip>110015</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Logistics University of PAPF Affiliated Hospital</name>
      <address>
        <city>Tianjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TEDA International Cardiovascular Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Asia Heart Hospital</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Medical College of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2013</study_first_submitted>
  <study_first_submitted_qc>October 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2013</study_first_posted>
  <results_first_submitted>December 11, 2015</results_first_submitted>
  <results_first_submitted_qc>January 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 18, 2016</results_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>412 subjects have enrolled and finished at 07Jul2014</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>SYNERGY Investigational Device (Test)</title>
          <description>SYNERGY Investigational Device (Test): percutaneous coronary intervention</description>
        </group>
        <group group_id="P2">
          <title>PROMUS Element Plus Investigational Device (Control)</title>
          <description>PROMUS Element Plus Investigational Device (Control): percutaneous coronary intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SYNERGY Investigational Device (Test)</title>
          <description>SYNERGY Investigational Device (Test): percutaneous coronary intervention</description>
        </group>
        <group group_id="B2">
          <title>PROMUS Element Plus Investigational Device (Control)</title>
          <description>PROMUS Element Plus Investigational Device (Control): percutaneous coronary intervention</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="205"/>
            <count group_id="B2" value="207"/>
            <count group_id="B3" value="412"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.41" spread="8.76"/>
                    <measurement group_id="B2" value="57.89" spread="9.19"/>
                    <measurement group_id="B3" value="58.15" spread="8.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The In-stent Late Loss Measured by Quantitative Coronary Angiography</title>
        <time_frame>at 9 months post-index procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SYNERGY Investigational Device (Test)</title>
            <description>SYNERGY Investigational Device (Test): percutaneous coronary intervention</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element Plus Investigational Device (Control)</title>
            <description>PROMUS Element Plus Investigational Device (Control): percutaneous coronary intervention</description>
          </group>
        </group_list>
        <measure>
          <title>The In-stent Late Loss Measured by Quantitative Coronary Angiography</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.33"/>
                    <measurement group_id="O2" value="0.17" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR) Rate</title>
        <description>Target lesion revascularization is any ischemia-driven repeat percutaneous intervention, to improve blood flow, of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
        <time_frame>12 months post-index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SYNERGY Investigational Device (Test)</title>
            <description>SYNERGY Investigational Device (Test): percutaneous coronary intervention</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element Plus Investigational Device (Control)</title>
            <description>PROMUS Element Plus Investigational Device (Control): percutaneous coronary intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR) Rate</title>
          <description>Target lesion revascularization is any ischemia-driven repeat percutaneous intervention, to improve blood flow, of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Target Lesion Failure (TLF) Rate</title>
        <description>Target lesion failure is any ischemia-driven revascularization of the target lesion, MI (Q-wave and non–Q-wave) related to the target vessel, or (cardiac) death.</description>
        <time_frame>12 months post-index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SYNERGY Investigational Device (Test)</title>
            <description>SYNERGY Investigational Device (Test): percutaneous coronary intervention</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element Plus Investigational Device (Control)</title>
            <description>PROMUS Element Plus Investigational Device (Control): percutaneous coronary intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Failure (TLF) Rate</title>
          <description>Target lesion failure is any ischemia-driven revascularization of the target lesion, MI (Q-wave and non–Q-wave) related to the target vessel, or (cardiac) death.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SYNERGY Investigational Device (Test)</title>
          <description>SYNERGY Investigational Device (Test): percutaneous coronary intervention</description>
        </group>
        <group group_id="E2">
          <title>PROMUS Element Plus Investigational Device (Control)</title>
          <description>PROMUS Element Plus Investigational Device (Control): percutaneous coronary intervention</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>coronary artery stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>mycardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>coronary artery dissection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>atriventricular block second degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>intracardiac thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>ventricular arthythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>coronary artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>sudden hearing loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>gastrooesophageeal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>plague shift</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>blood glucose icreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>lung neoplasm maligant</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>tension headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>glycosuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>nephrotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>renal failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>aortic intramural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>angina pectoria</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="205"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>others</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="205"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>others</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hanyaling</name_or_title>
      <organization>Shenyang Northern Hospital (The General Hospital of Shenyang Military Region)</organization>
      <phone>024-28897310</phone>
      <email>hanyl@medmail.com.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

